Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR58611A in Generalized Anxiety Disorder
NCT00266747Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of amibegron in generalized anxiety disorder (GAD), sponsored by Sanofi. Started Dec 2005; status: completed.
02
Drugs
amibegron
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00266747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266747.